Joseph Pidala
Moffitt Cancer Center · H. Lee Moffitt Cancer Center and Research Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Joseph Pidala as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:48 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04620681 · CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AMLH. Lee Moffitt Cancer Center and Research Institute · completed · Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT02891603 · A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune SuppressionH. Lee Moffitt Cancer Center and Research Institute · completed · Graft Vs Host Disease, GVHD · principal investigator
- Ph1NCT01795573 · Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host DiseaseH. Lee Moffitt Cancer Center and Research Institute · completed · Graft Versus Host Disease · principal investigator
- Ph2NCT01713400 · Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host DiseaseH. Lee Moffitt Cancer Center and Research Institute · completed · Graft vs. Host Disease · principal investigator
- Ph1/Ph2NCT01680965 · Ofatumumab as Primary Therapy of Chronic Graft Versus Host DiseaseH. Lee Moffitt Cancer Center and Research Institute · completed · Chronic Graft Versus Host Disease · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical Centers - UG1UG1HL108987 · NHLBI · H. LEE MOFFITT CANCER CTR & RES INST · fiscal years 2017 to 2026 · $214,179 awarded in 2026Same name and institution; not confirmed by an ID
- Adoptive Transfer of Donor Tregs Specific Against Host Alloantigens for PresentioR01HL114994 · NHLBI · H. LEE MOFFITT CANCER CTR & RES INST · fiscal years 2017 · $556,530 awarded in 2017Same name and institution; not confirmed by an ID
- Biologic Markers of Chronic Graft vs. Host Disease Therapeutic ResponseR03CA197539 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · fiscal years 2015 to 2016 · $86,000 awarded in 2016Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Targeting T-cell costimulation and cytokine activation to prevent GVHD and preserve GVLR01HL133823 · NHLBI · UNIVERSITY OF MINNESOTA · PI Brian C Betts · fiscal years 2016 to 2020Named on NCT02891603
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:48 UTC. The ranking covers the 200 most relevant of 46 PubMed records, and a shared surname and initials can bring in a namesake. All 46 on PubMed
- 296 citationsRCR 10.5
- 251 citationsRCR 11.0
- National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.J Clin Oncol · 2021196 citationsRCR 12.1
- 183 citationsRCR 5.5
- Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant · 2016172 citationsRCR 7.4
- Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant · 2016154 citationsRCR 6.3
- A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation.Haematologica · 201283 citationsRCR 2.2
- 75 citationsRCR 3.5
- A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.Clin Cancer Res · 201671 citationsRCR 2.7
- 63 citationsRCR 1.9